The illustration of the successful mobilization of hematopoietic stem cells using plerixafor and pegfilgrastim in the patient with non-hodgkin's lymphoma


Cite item

Full Text

Abstract

In our clinical example, we studied the possibility of early treatment intensification, through the use of a new combination pegfilgrastim and plerixafor as a regime of mobilization. Within 4 days (after a single injection pegfilgrastim 6 mg in D1) we observed a gradual increase in the content of CD34+-cells in peripheral blood, but only after injection plerixafor (D4) at a rate of 0.24 mg/kg, we were able to initiate the apheresis procedure. Number of collected CD34+-cells was 14,9106 that is more than adequate for a quick and stable hematopoietic recovery after a course HDC and timely recovery of the cellular composition of the blood of this patient (D10) indicated the quality of hematopoietic assembled material. Thus, the combination pegfilgrastim and plerixafor - a simple and effective way to mobilize hematopoietic stem cells in peripheral blood.

About the authors

M S Motalkina

N.N. Petrov Research Institute of Oncology, of the Ministry of Health of the Russian Federation

Email: margarita.motalk@mail.ru
аспирант НИИ онкологии им Н.Н. Петрова Минздрава России, Санкт-Петербург 197758, Russian Federation, Saint Petersburg, p. Pesochnyi, ul. Leningradskaia, d. 68

S A Kulyova

N.N. Petrov Research Institute of Oncology, of the Ministry of Health of the Russian Federation; SBEI HPE St.Petersburg State Pediatric Medical University of the Ministry of Health of Russia

д.м.н., старший научный сотрудник НИИ онкологии им Н.Н. Петрова Минздрава России, Санкт-Петербург 194100, Russian Federation, Saint Petersburg, ul. Litovskaia, d. 2

S M Alexeev

N.N. Petrov Research Institute of Oncology, of the Ministry of Health of the Russian Federation

к.м.н., научный сотрудник НИИ онкологии им Н.Н. Петрова Минздрава России, Санкт-Петербург 197758, Russian Federation, Saint Petersburg, p. Pesochnyi, ul. Leningradskaia, d. 68

I S Zuzgin

N.N. Petrov Research Institute of Oncology, of the Ministry of Health of the Russian Federation

зав. химиотерапевтическим отд-нием гематологии, онкологии и трансплантации костного мозга НИИ онкологии им Н.Н. Петрова Минздрава России, Санкт-Петербург 197758, Russian Federation, Saint Petersburg, p. Pesochnyi, ul. Leningradskaia, d. 68

L V Filatova

N.N. Petrov Research Institute of Oncology, of the Ministry of Health of the Russian Federation

к.м.н., старший научный сотрудник НИИ онкологии им Н.Н. Петрова Минздрава России, Санкт-Петербург 197758, Russian Federation, Saint Petersburg, p. Pesochnyi, ul. Leningradskaia, d. 68

A S Zhabina

N.N. Petrov Research Institute of Oncology, of the Ministry of Health of the Russian Federation

к.м.н., научный сотрудник НИИ онкологии им Н.Н. Петрова Минздрава России, Санкт-Петербург 197758, Russian Federation, Saint Petersburg, p. Pesochnyi, ul. Leningradskaia, d. 68

A A Zverkova

N.N. Petrov Research Institute of Oncology, of the Ministry of Health of the Russian Federation

врач-гематолог НИИ онкологии им Н.Н. Петрова Минздрава России, Санкт-Петербург 197758, Russian Federation, Saint Petersburg, p. Pesochnyi, ul. Leningradskaia, d. 68

I V Ishmatova

N.N. Petrov Research Institute of Oncology, of the Ministry of Health of the Russian Federation

врач-гематолог НИИ онкологии им Н.Н. Петрова Минздрава России, Санкт-Петербург 197758, Russian Federation, Saint Petersburg, p. Pesochnyi, ul. Leningradskaia, d. 68

A A Rjazankina

N.N. Petrov Research Institute of Oncology, of the Ministry of Health of the Russian Federation; SBEI HPE North-Western State Medical University named after I.I.Mechnikov

191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41

A S Artemyeva

N.N. Petrov Research Institute of Oncology, of the Ministry of Health of the Russian Federation

врач-патологоанатом НИИ онкологии им Н.Н. Петрова Минздрава России 197758, Russian Federation, Saint Petersburg, p. Pesochnyi, ul. Leningradskaia, d. 68

T Yu Semiglazova

N.N. Petrov Research Institute of Oncology, of the Ministry of Health of the Russian Federation; SBEI HPE North-Western State Medical University named after I.I.Mechnikov

191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41

References

  1. Wuchter P, Ran D, Bruckner T et al. Poor mobilization of hematopoietic stem cells - definitions, incidence, risk factors, and impact on out - come of autologous transplantation. Biol Blood Marrow Transplant 2010; 16: 490-9.
  2. Nademanee A.P, Di Persio J.F, Maziarz R.T et al. Plerixafor plus granulocyte colony - stimulating factor vs. placebo plus granulocyte colony - stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biol Blood Marrow Transplant 2012; 18 (10): 1564-72.
  3. Покровская О.С. Механизм действия и клиническая эффективность антагониста хемокинового рецептора CXCR4 плерик - сафора при мобилизации гемопоэтических стволовых клеток. Клин. онкогематология. 2012; 4: 371-9.
  4. Bakany S.M, Demirer T et al. Novel agents and approaches for stem cell mobilization in normal donors and patients. J Bone Marrow Transplant 2012; 47: 1154-63.
  5. Haioun C, Lepage E, Gisselbrecht C. Survival benefit of high dose therapy in poor risk aggressive non Hodgkins lymphoma: final analysis of the prospective LNH872 protocola groupe dEtude des lymphomes de I’Adulte study. J Clin Oncol 2000; 18 (16): 3025-30.
  6. Herbert K.E, Demosthenous L, Wiesner G et al. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial. J Bone Marrow Transplant 2014; 49 (8): 1056-62.
  7. Gisselbrecht C, Lepage E, Molina T et al. Shortened first line high dose chemotherapy for patients poor prognosis aggressive lymphoma. J Clin Oncol 2002; 20 (10): 2472-9.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies